William Blair Reiterates Market Perform Rating for FibroGen (NASDAQ:FGEN)

William Blair reissued their market perform rating on shares of FibroGen (NASDAQ:FGEN) in a report issued on Wednesday morning,RTT News reports.

Separately, StockNews.com began coverage on shares of FibroGen in a research report on Wednesday, November 6th. They set a “hold” rating for the company.

FibroGen Price Performance

NASDAQ FGEN opened at $0.33 on Wednesday. The business has a 50 day moving average price of $0.36 and a 200 day moving average price of $0.71. The company has a market capitalization of $33.73 million, a P/E ratio of -0.27 and a beta of 0.72. FibroGen has a 1-year low of $0.18 and a 1-year high of $2.93.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.21. The firm had revenue of $46.33 million during the quarter, compared to analysts’ expectations of $34.00 million. During the same quarter in the prior year, the business earned ($0.52) EPS. On average, research analysts expect that FibroGen will post -1.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On FibroGen

A number of large investors have recently bought and sold shares of the stock. Acadian Asset Management LLC lifted its position in shares of FibroGen by 34.4% in the second quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock valued at $2,997,000 after acquiring an additional 860,854 shares in the last quarter. AQR Capital Management LLC lifted its holdings in FibroGen by 139.6% in the 2nd quarter. AQR Capital Management LLC now owns 1,320,866 shares of the biopharmaceutical company’s stock valued at $1,179,000 after purchasing an additional 769,586 shares in the last quarter. Assenagon Asset Management S.A. acquired a new stake in shares of FibroGen during the 3rd quarter worth about $307,000. XTX Topco Ltd purchased a new stake in shares of FibroGen during the second quarter worth about $424,000. Finally, Cubist Systematic Strategies LLC raised its position in shares of FibroGen by 3,906.9% in the second quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock valued at $256,000 after buying an additional 280,161 shares during the last quarter. Institutional investors and hedge funds own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.